ValuEngine lowered shares of Sangamo Therapeutics (NASDAQ:SGMO) from a strong-buy rating to a buy rating in a research report released on Thursday morning.

A number of other equities analysts also recently weighed in on the company. Bank of America started coverage on Sangamo Therapeutics in a report on Wednesday, June 20th. They issued a buy rating and a $24.00 target price on the stock. Cowen reiterated a buy rating on shares of Sangamo Therapeutics in a report on Monday, July 23rd. BidaskClub downgraded Sangamo Therapeutics from a hold rating to a sell rating in a report on Thursday, July 26th. Zacks Investment Research upgraded Sangamo Therapeutics from a sell rating to a hold rating in a report on Tuesday, August 14th. Finally, Wedbush reiterated a hold rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a report on Thursday, August 9th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $21.00.

Shares of SGMO opened at $13.75 on Thursday. The stock has a market capitalization of $1.40 billion, a PE ratio of -19.64 and a beta of 2.95. Sangamo Therapeutics has a fifty-two week low of $11.30 and a fifty-two week high of $27.50. The company has a debt-to-equity ratio of 0.07, a quick ratio of 7.24 and a current ratio of 7.24.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The business had revenue of $21.42 million during the quarter, compared to analyst estimates of $21.43 million. Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. Sangamo Therapeutics’s revenue for the quarter was up 159.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.17) EPS. sell-side analysts expect that Sangamo Therapeutics will post -0.69 EPS for the current fiscal year.

In related news, VP Edward R. Conner sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, August 6th. The stock was sold at an average price of $13.45, for a total value of $67,250.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director H Stewart Parker purchased 2,000 shares of the stock in a transaction that occurred on Friday, September 7th. The stock was purchased at an average cost of $13.52 per share, with a total value of $27,040.00. The disclosure for this purchase can be found here. Insiders sold a total of 30,000 shares of company stock worth $446,250 in the last quarter. 1.20% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in SGMO. Riverhead Capital Management LLC grew its stake in shares of Sangamo Therapeutics by 218.0% in the 2nd quarter. Riverhead Capital Management LLC now owns 8,267 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 5,667 shares in the last quarter. Mount Yale Investment Advisors LLC grew its stake in shares of Sangamo Therapeutics by 2,202.8% in the 2nd quarter. Mount Yale Investment Advisors LLC now owns 8,359 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 7,996 shares in the last quarter. NumerixS Investment Technologies Inc bought a new stake in shares of Sangamo Therapeutics in the 2nd quarter valued at approximately $125,000. Tyers Asset Management LLC grew its stake in shares of Sangamo Therapeutics by 301.3% in the 2nd quarter. Tyers Asset Management LLC now owns 9,632 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 7,232 shares in the last quarter. Finally, First Mercantile Trust Co. grew its stake in shares of Sangamo Therapeutics by 93.7% in the 1st quarter. First Mercantile Trust Co. now owns 7,666 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 3,708 shares in the last quarter. 63.95% of the stock is owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Featured Article: What is a Tariff?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.